Diabetes and Alzheimer's Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?

• Päätekijät: Maria Assunta Potenza (Tekijä), Luca Sgarra (Tekijä), Vanessa Desantis (Tekijä), Carmela Nacci (Tekijä), Monica Montagnani (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2021-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.
• Notes: 10.3390/antiox10081257; 2076-3921
• Keywords: mitochondrial dysfunction; type 2 diabetes (T2DM); Alzheimer's disease (AD); Therapeutics. Pharmacology; RM1-950
• Source: Antioxidants, Vol 10, Iss 8, p 1257 (2021)

A growing number of clinical and epidemiological studies support the hypothesis of a tight correlation between type 2 diabetes mellitus (T2DM) and the development risk of Alzheimer's disease (AD). Indeed, the proposed definition of Alzheimer's disease as type 3 diabetes (T3D) underlines the key role played by deranged insulin signaling to accumulation of aggregated amyloid beta (Aβ) peptides in the senile plaques of the brain. Metabolic disturbances such as hyperglycemia, peripheral hyperinsulinemia, dysregulated lipid metabolism, and chronic inflammation associated with T2DM are responsible for an inefficient transport of insulin to the brain, producing a neuronal insulin resistance that triggers an enhanced production and deposition of Aβ and concomitantly contributes to impairment in the micro-tubule-associated protein Tau, leading to neural degeneration and cognitive decline. Furthermore, the reduced antioxidant capacity observed in T2DM patients, together with the impairment of cerebral glucose metabolism and the decreased performance of mitochondrial activity, suggests the existence of a relationship between oxidative damage, mitochondrial impairment, and cognitive dysfunction that could further reinforce the common pathophysiology of T2DM and AD. In this review, we discuss the molecular mechanisms by which insulin-signaling dysregulation in T2DM can contribute to the pathogenesis and progression of AD, deepening the analysis of complex mechanisms involved in reactive oxygen species (ROS) production under oxidative stress and their possible influence in AD and T2DM. In addition, the role of current therapies as tools for prevention or treatment of damage induced by oxidative stress in T2DM and AD will be debated.